Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12527430 | 0.96 | SLC6A4 (0.67) | SLC6A4HTR1A | |
| SCHEMBL30320095 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL4351901 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL15543730 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL5234124 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL30468389 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL6879916 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL3103741 | 0.85 | SLC6A4 (0.73) | SLC6A4HTR1A | |
| SCHEMBL5791054 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL24328228 | 0.84 | SLC6A4 (0.59) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| WO-2006061379-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | SLC6A4 26/4885HTR1A 4/4885MPO 3062/4885 |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | SLC6A4 33/4885HTR1A 5/4885MPO 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.